That conversation has been going on since long before COVID-19. For example age is one factor in allocating scarce transplant organs. Other countries with socialized healthcare systems sometimes explicitly use Quality Adjusted Life Years (QALY) in deciding whether to pay for expensive treatments for elderly patients.
So is he. QALY analysis is used to allocate all treatment in places like the UK, realistically in other places too. Basically a very expensive treatment that is only expected to increase your lifespan by a few months if you're already very elderly may not get funded if there are other interventions with better cost/benefit ratios available in the queue. This obviously affects nearly 100% of the population in the sense that most people will make it to old age, and even the non-elderly are affected by getting treatment they otherwise might not have done.
